Connor, Clark & Lunn Investment Management Ltd. Rubius Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 05, 2022	BUY	$0.79 - $5.98 $234,539 - $1.78 Million	296,886 Added 521.52%	353,813 $301,000
Q1 2022 May 12, 2022	BUY	$4.25 - $10.4 $241,939 - $592,040	56,927 New	56,927 $314,000

Others Institutions Holding RUBY

# of Institutions

Shares Held

325

Call Options Held

Put Options Held

American Portfolios Advisors Holbrook, NY

325
Shares

$0
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Rubius Therapeutics, Inc.

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

More about RUBY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account